Fecal microbiota, live-jslm（Rebiotix）

N/A

Report date: 2022/12/01 09:55:25

Base Information

Drug NameFecal microbiota, live-jslm（Rebiotix）
Drug Alias NameRBX2660Microbiota suspension - RebiotixMicrobiota restoration therapy - RebiotixREBYOTARBX-2660
ClassificationNatural product/Extract > Microbial extractBiologics > Live Biotherapeutic
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsEnterocolitisUrinary Tract InfectionsCommunicable Diseases +[5] 
Global Approved IndicationsClostridium Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/11/30
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesUniversity Of AlbertaRebiotix Inc
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineRebiotix IncFerring Pharmaceuticals Ltd
Inactive CompaniesFerring Bv
Active IndicationsUrinary Tract InfectionsCommunicable DiseasesClostridium Infections
Inactive IndicationsEnterocolitisInfections

Other Information

ATC CodeN/A
Related LinksN/A